The purpose of this review is to outline the recent developments in the field of extraesophageal reflux disease and provide clinically relevant recommendations. The recommendations outlined in this review are based on expert opinion and on relevant publications from PubMed and EMbase. The Clinical Practice Updates Committee of the American Gastroenterological Association proposes the following recommendations: Best Practice Advice 1: The role of a gastroenterologist in patients referred for evaluation of suspected extra esophageal symptom is to assess for gastroesophageal etiologies that could contribute to the presenting symptoms. Best Practice Advice 2: Non-GI evaluations by ENT, pulmonary and/or allergy are essential and often should be performed initially in most patients as the cause of the extraesophageal symptom is commonly multifactorial or not esophageal in origin. Best Practice Advice 3: Empiric therapy with aggressive acid suppression for 6-8 weeks with special focus on response of the extraesophageal symptoms can help in assessing association between reflux and extraesophageal symptoms. Best Practice Advice 4: No single testing methodology exists to definitively identify reflux as the etiology for the suspected extra esophageal symptoms. Best Practice Advice 5: Constellation of patient presentation, diagnostic test results and response to therapy should be employed in the determination of reflux as a possible etiology in extra esophageal symptoms. Best Practice Advice 6: Testing may need to be off or on proton pump inhibitor (PPI) therapy depending on patients' presenting demographics and symptoms in assessing the likelihood of abnormal gastroesophageal reflux.
A. On therapy testing may be considered in those with high probability of baseline reflux (those with previous esophagitis, Barrett's esophagus or abnormal pH). B. Off therapy testing may be considered in those with low probability of baseline reflux with the goal of identifying moderate to severe reflux at baseline. Best Practice Advice 7: Lack of response to aggressive acid suppressive therapy combined with normal pH testing off therapy or impedance-pH testing on therapy significantly reduces the likelihood that reflux is a contributing etiology in presenting extraesophageal symptoms. Best Practice Advice 8: Surgical fundoplication is discouraged in those with extra esophageal reflux symptoms unresponsive to aggressive PPI therapy.
Best Practice Advice 9: Fundoplication should only be considered in those with a mechanical defect (e.g., hiatal hernia), moderate to severe reflux at baseline off PPI therapy who have continued reflux despite PPI therapy and have failed more conservative non-GI treatments.
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T he concept of extraesophageal manifestations secondary to gastroesophageal reflux disease is opaque and multifaceted. A long list of extraesophageal symptoms has been associated with gastroesophageal reflux disease (GERD) ( Table 1 ). There is evidence-based support for some but many others are linked by association only. The latter group is marked by studies demonstrating a high prevalence of heartburn symptoms and/or increased esophageal acid exposure measured on ambulatory pH monitoring. There is stronger evidence for the association of reflux disease with symptoms of asthma, cough, and hoarseness. When less stringent criteria are used the attributions are broader and could include sore throat, sinusitis, ear pain, and pulmonary fibrosis.
Part of the confusion lies in controversy over the putative mechanism by which esophageal reflux causes these extraesophageal symptoms. The most intuitive theory is that direct contact of gastric refluxate with structures proximal to the esophagus leads to caustic injury of structures, such as the pharynx, larynx, and bronchial tree. Yet, investigators disagree on the role and amount of acid required for injury and whether nonacid components, such as pepsin or bile, also contribute. 1, 2 There is also theory that structures superior to the upper esophageal sphincter require little or even physiologic acid exposure for injury because of a lack of intrinsic defense mechanisms present when compared with the esophagus. 3, 4 Another putative mechanism is neurogenic stimulation or hypersensitivity of these structures. 5 For example, esophageal distention by a bolus of refluxate may activate neurons that innervate bronchial constriction and sensitize pharyngeal or respiratory epithelial afferent pathways. These theories arise from evidence that suggests that a proximal esophageal distribution of reflux is not required for extraesophageal symptoms to occur. Furthermore, administration of antagonists of this reflex arc may be effective in reducing symptoms. Nevertheless, such data are not universally supported and granularity is lacking with regard to the volume of bolus required or whether this reflex can be a sole cause of these symptoms.
One of the key unanswered questions is appropriate timing of esophageal evaluation for potential extraesophageal manifestations. Because such symptoms as cough can have a multitude of causes working alone or in concert, physicians need to decide on the likelihood that GERD is the primary contributor before initiating therapy or evaluation with endoscopy and ambulatory pH monitoring. For example, one of the rare double-blind studies using proton pump inhibitors (PPIs) for postnasal drainage showed a benefit but only after patients underwent extensive prior evaluation for other etiologies, such as negative radioallergosorbent testing, insufficient response to nasal corticosteroids, allergy shots and antihistamines, and normal sinus evaluation by computed tomography. 6 This study questioned whether one of the major factors that contributes to the controversy of GERDassociated extraesophageal manifestations is that other potential causes have not been adequately evaluated and/or treated before referral. Additionally, symptom assessment scales used in esophageal syndromes cannot be reliable in those with extraesophageal symptoms.
This practice of early treatment with PPIs or referral to a gastroenterologist for testing occurs commonly. The 2002 position statement of the Committee on Speech, Voice and Swallowing Disorders of the American Academy of Otolaryngology stated that the diagnosis of laryngopharyngoreflux (LPR) can be made on the basis of patient symptoms, laryngeal findings, and/or pH probe results and recommended treatment with twice-daily PPI for a minimum initial period of 6 months. 7 As a result, aggressive pursuit of gastroesophageal reflux of these symptoms continues despite more recent data challenging the accuracy of laryngeal findings, 8 empiric trials of PPIs, 9 and pH monitoring 10 to establish causation. The goal of this Clinical Practice Update Committee review is to critically analyze current data evaluating the relationship of gastroesophageal reflux to proposed extraesophageal manifestations.
Diagnostic Tests and Challenges Associated in Establishing Causal Link
There are no established diagnostic tests that unequivocally link any suspected extraesophageal symptom to GERD. Diagnostic tests used in evaluation of patients with extraesophageal symptoms (Table 2) suffer from either lack of sensitivity or specificity and have limited associated treatment outcomes. Nevertheless, testing is needed, and often in combination, to support or refute this diagnosis. We do not discuss the use of barium esophagography because of its reduced sensitivity in GERD detection and because its utility is limited to evaluation of dysphagia and hiatal hernia size and type, which is beyond the scope of this report.
Laryngoscopy
Laryngoscopy is considered to be essential by otolaryngologists for the diagnosis of extraesophageal reflux extraesophageal manifestations because mucosal injury is one of the main diagnostic criteria of LPR. Indeed, most ear, nose, and throat specialists strongly believe that laryngeal signs, such as posterior commissure hypertrophy, erythema/hyperemia, vocal fold edema, diffuse laryngeal edema, posterior commissure hypertrophy, and granulation/granuloma, reflect the presence of significant pharyngolaryngeal inflammation and are reliable signs of reflux-related symptoms. However, they can be present in up to 86% of asymptomatic subjects 11 and both the intraobserver and interobserver reproducibility of these signs is poor. The Reflux Finding Score based on select laryngoscopic signs is used by some 12, 13 ; however, 
Esophagogastroduodenoscopy
Esophagogastroduodenoscopy has a low diagnostic yield in the context of suspected extraesophageal manifestations of GERD. Although the presence of esophagitis is evidence of GERD it does not establish a link between reflux and extraesophageal symptoms. Indeed, if endoscopic esophagitis can be found in 40% of patients with asthma 15 and 20% of patients with primary extraesophageal symptoms, 16 it can also be observed in up to 20% of asymptomatic subjects (silent esophagitis). 17 Conversely, it is a minority of patients with erosive esophagitis who have symptoms of LPR. The prevalence of esophagitis may be even lower because most patients referred to gastrointestinal specialists have previously received 1 or several courses of PPIs treatment prescribed by either general practitioners or otolaryngologists. Moreover, the presence of esophagitis does not predict the response to antisecretory therapy.
Summary. Abnormalities seen on endoscopy have poor predictive value for determination of GERD as the cause of extraesophageal symptoms.
Ambulatory pH Monitoring
Several techniques have been developed to detect reflux events in the distal and proximal esophagus and pharynx.
Catheter-based pH monitoring. Catheter-based pH monitoring is performed with a pH probe positioned in the distal esophagus to identify patients with pathologic acid reflux and to assess temporal relationships between reflux events and symptoms. However, most laryngeal symptoms do not have a sudden onset (eg, hoarseness, throat clearing, dysphonia) and a reliable symptom association analysis is not possible in many patients. It is theoretically more applicable for such symptoms as cough or asthma but the temporal association implies reliable activation of the event marker by the patient in a timely and consistent manner. Indeed, the use of acoustic 18 or manometric 19 devices has demonstrated that up to 90% of cough events were not adequately reported by the patients with the event marker. Conventional distal 24-hour esophageal pH-monitoring cannot be considered as reliable for the diagnosis of LPR and reflux-related asthma. Indeed, all randomized studies have shown that abnormal distal esophageal exposure does not predict the response of extraesophageal symptoms to PPIs, although it can be demonstrated in 30%-50% of patients with suspected LPR 20, 21 and reflux-related asthma. 22, 23 Although randomized controlled trials failed to demonstrate any benefit of antisecretory therapy in patients with chronic cough, abnormal esophageal acid exposure during 24-hour pH monitoring may help to identify a subgroup of patients more likely to have reflux-related chronic cough.
24
Proximal and pharyngeal pH monitoring. In line with the theory of a direct reflux-related caustic injury of the bronchial tree and the pharyngolaryngeal mucosa as a cause of extraesophageal manifestations measuring acid exposure of the proximal esophagus and/or the pharynx may be relevant in the evaluation of these patients. 7 This can be obtained with a dual sensor pH monitor to simultaneously measure distal and proximal esophageal acid exposure, or with a single pharyngeal probe. However, methods for proximal pH recordings have many technical limitations, such as inaccurate and/or irreproducible probe positioning, swallow-related artifacts, drift in pH values, and controversies about normal values. [25] [26] [27] In a study with esophageal and pharyngeal pHimpedance monitoring in healthy subjects, more than 90% of pharyngeal pH drops below 4 and 5 that could be interpreted as reflux were related to swallows with only a minority related to gastroesophageal and pharyngeal reflux events. 28 Enthusiastic results have been reported with the Restech Dx-pH device (Houston, TX), a pharyngeal pH probe designed to detect aerosolized and liquid acid reflux, 29 suggesting that it could help to select patients for antireflux surgery. 30, 31 However, several studies have demonstrated pharyngeal reflux occurring without events detected by esophageal pH-impedance probes used simultaneously suggesting a nonreflux cause of pH drop. 32, 33 A recent study demonstrated multiple pathologic pharyngeal acid events in patients after total gastrectomy, further raising questions about the accuracy of the technique. 34 Considering these limitations, a recent consensus from an international group of experts considered that "there is no clear evidence that dual probe pH monitoring is of additional value above distal pH probe measurement alone" and that "measurement of airway and pharyngeal pH cannot be recommended to diagnose gastro-esophageal reflux episodes extending to the pharynx." 35 
Combined pH and Impedance Monitoring
Combined esophageal pH-impedance monitoring. Combined pH and impedance monitoring is considered the best tool to characterize gastroesophageal reflux because it can detect all types of reflux events (acidic, weakly acidic, weakly alkaline) and determine the proximal extent of the refluxate within the esophagus. 35 However, the role of this device in establishing a link between extraesophageal symptoms and reflux events is equally uncertain regardless of whether performed on or off PPI therapy. As a whole, studies in patients with symptoms refractory to PPIs have shown that 30%-40% have symptoms associated with nonacid reflux, around 10% have symptoms associated with acid reflux, and 50%-60% of patients have symptoms that cannot be associated with any type of gastroesophageal reflux. 36, 37 In patients with laryngeal symptoms, including globus, the added value of impedance compared with pH alone is limited. Similar to what was reported with pH-alone monitoring, less than 40% of patients with suspected extraesophageal manifestations have an abnormal pHimpedance study. 38 Moreover, it was shown that only heartburn and abnormal pH parameters were associated with a favorable outcome after surgery for extraesophageal manifestations, whereas impedance parameters had no value. 39 Conflicting results have been reported to date regarding the number of reflux events with high proximal extent detected in patients with suspected extraesophageal manifestations. 40, 41 The added value of impedance monitoring is probably higher in patients with unexplained cough, especially if a cough detection device is used. In a cohort of 100 consecutive patients, Blondeau et al 42 found abnormal acid reflux in 45 and abnormal nonacid reflux in 24. Herregods et al 43 recently reported that cough episodes were more frequently associated with high proximal extent of the refluxate, a higher volume clearance, and a higher acidic and volume burden in the 15-30 minutes preceding the occurrence of cough. These observations may explain why some patients do not respond to PPI therapy. However, the mechanisms leading to the occurrence of cough are more complex than a simple temporal relationship. Using a cough detection device, Smith et al 5 observed that 56% of patients with unexplained cough have a positive symptom association for reflux following a cough, thus showing that reflux may be induced by cough. In the same study, a reflux-cough sequence could be demonstrated in approximately 50% of patients, but the only difference between patients with and without temporal association was a more sensitive cough reflex. Similarly, Francis et al 44 showed that reflux was a relatively small contributor to subsequent cough as compared with phonation or cough itself, thus supporting the concept of airway hypersensitivity in these patients.
Combined esophageal and pharyngeal pH-impedance monitoring. To detect reflux events reaching the pharynx, bifurcated pharyngeal impedance catheters have been designed allowing reliable positioning of the impedance and pH sensors above the upper and lower esophageal sphincters regardless of subject height. There were some significant discrepancies between the first set of short series published with this technique in control subjects and patients with suspected extraesophageal manifestations. [45] [46] [47] Normal values of pharyngeal reflux have been determined in 46 asymptomatic volunteers studied "off" therapy and after 2 weeks of esomeprazole, 40 mg twice a day. 48 However, swallows and air trapping in the pharynx create many artifacts and hamper adequate interpretation of pharyngeal impedance tracings, and consequently, poor interobserver reproducibility was reported. Pharyngeal impedance was used in a study in 24 consecutive patients with suspected extraesophageal manifestations refractory to PPI therapy 49 in whom pharyngeal and esophageal reflux patterns were identical to those of healthy subjects, both off and on PPI therapy. Therefore, in patients with suspected extraesophageal reflux refractory to PPIs, combined esophageal and pharyngeal pH-impedance cannot detect abnormal pharyngeal reflux.
Testing "Off" or "On" Therapy?
Whether ambulatory reflux testing should be performed "off" or "on" antisecretory therapy is still a matter of debate. Testing "off" therapy allows documentation of baseline reflux. A negative pH or pHimpedance monitoring study "off" therapy in patients not responding to PPIs significantly reduces the likelihood that reflux is a contributing cause in presenting extraesophageal symptoms. Testing "on" therapy gives information on control of reflux and the temporal association between persisting symptoms and reflux events. It is of note that there is no consensus regarding the definition of abnormal pH-impedance testing "on" therapy (ie, high number of reflux events, low baseline impedance value, positive symptom association analysis). In clinical practice, "off" therapy testing may be considered in patients without previously documented or suspected GERD, whereas "on" therapy testing may be a better option in patients with pathologic reflux (eg, previous abnormal pH testing, significant esophagitis, large hiatal hernia, or Barrett's esophagus). Even if pathologic reflux is demonstrated, no single testing methodology can definitively identify reflux as the cause for the suspected extraesophageal symptoms.
Summary. Ambulatory pH/impedance monitoring and pharyngeal pH monitoring have limited ability to establish GERD as the cause of an extraesophageal symptom. The main role of testing is to document the absence of GERD. Testing "on" or "off" PPI therapy is dependent on the pretest probability that underlying GERD is present.
Novel Tests (Salivary Pepsin, Mucosal Impedance)
The detection of pepsin in the saliva may be an elegant and noninvasive method for the diagnosis of GERD. Most available data have been obtained in patients with typical reflux symptoms. In a recent study, onethird of control subjects had a positive pepsin sample compared with 78%, 80%, and 33% of patients with GERD, hypersensitive esophagus, and functional heartburn, respectively, thus providing a sensitivity of 78.6% and a specificity of 64.9% for diagnosis of reflux-related symptoms. 50 The specificity of the test increased to 98.2% when higher pepsin concentration was considered. A similar study reported a positive predictive value of 81% and negative predictive value of 78% of salivary pepsin test for the diagnosis of GERD. 51 Another study in pediatric patients demonstrated a positive correlation between positive pepsin samples and impedance-pH monitoring parameters, but observed wide variations in pepsin concentrations according to the timing of sampling. 52 If salivary pepsin detection has promise for the diagnosis of GERD, its potential utility for the diagnosis of extraesophageal reflux remains to be determined because conflicting results have been reported to date. In patients with suspected extraesophageal reflux salivary pepsin had a sensitivity of 78% and specificity of 53% to predict a high Reflux Finding Score and salivary pepsin concentration was correlated to the severity of laryngeal inflammation. 53 Another study reported no difference in the rate of detecting pepsin when comparing 15 subjects with laryngeal symptoms with 18 control subjects but the mean concentration of salivary pepsin was significantly higher when typical reflux symptoms were present. 54 Finally, in a pediatric population of 50 children, 42% were positive for salivary pepsin but there was no significant relationship between the presence of salivary pepsin and extraesophageal symptoms or pH-impedance parameters. 55 The role of salivary pepsin detection for the diagnosis of extraesophageal reflux remains to be established.
Mucosal impedance (MI) is a novel technology that measures changes in mucosal current conduction as an assessment of epithelial integrity. Impaired mucosal integrity is well described in GERD or other causes of diffuse esophageal injury, such as eosinophilic esophagitis. [56] [57] [58] MI is measured with a catheter or balloonbased probe placed during endoscopy that allows direct contact of sensors on the catheter with the mucosa. This tool adds approximately 1 minute to the examination and each MI measurement takes 5 seconds, which allows for a rapid derivation of data without a standard overnight pH/impedance catheter as has been previously used to assess MI. 59 Initial studies with this device have found excellent results in distinguishing GERD and non-GERD from normal. 56 In addition, MI is capable of distinguishing eosinophilic esophagitis from GERD without the need for tissue biopsies. 60 A recent study using MI in patients with extraesophageal reflux symptoms showed that this device can detect the presence of reflux in this difficult to manage group of patients. 61 Future studies are needed with this device to establish if it can establish a causal link between esophageal or laryngeal mucosal changes and response to acid-suppressive therapy.
Summary. There is no clear role for novel tests in establishing GERD as the cause of extraesophageal symptoms.
Treatment Challenges
The goals of treatment in reflux disease, independent of presenting symptom, are to relieve symptoms, heal esophagitis, and prevent recurrence of symptoms and future complications. The options to achieve these goals include lifestyle modification, medical therapy, endoscopic antireflux procedures, and surgical interventions (Table 3) . Endoscopic antireflux procedures are not discussed given limited available data in those with extraesophageal reflux.
Lifestyle Modification
Lifestyle modification is an important component of treating patients suspected of having reflux-related symptoms. However, high-quality data are lacking providing clear evidence for their efficacy. [62] [63] [64] [65] [66] A systematic review examining the impact of lifestyle modification in GERD suggested there is a lack of or weak evidence that cessation of tobacco, alcohol, chocolate, caffeine or coffee, citrus, mint, or spicy food results in improvement of symptoms or physiological reflux. 62 Another systematic review concluded that there was lack of evidence that consumption of carbonated beverages causes or is associated with GERD. 65 There is, however, some evidence that controlling weight might reduce reflux. It is established that weight gain results in GERD symptoms and complications 67 and weight loss reduces reflux symptoms. 67, 68 Data regarding the role of lifestyle modification in extraesophageal reflux are even more suspect. In a recent study of patients with extraesophageal reflux. Chappity et al 69 showed that lifestyle modification alone is less effective than PPI therapy in combination with lifestyle modification. One small study of 5 patients with vocal cord granuloma reported complete resolution of extraesophageal symptoms and granuloma within 6 months of combined PPI and lifestyle measures including elevation of head of bed. 70 In a cross-sectional study of 223 patients with suspected reflux-related extraesophageal symptoms, Aslam et al 71 showed that esophageal acid exposure was significantly and nonlinearly associated with body mass index. Increase in esophageal acid exposure was greatest among overweight patients, which reached a plateau in obese patients, implying that weight loss even in a small amount might reduce the degree of acid exposure in those with extraesophageal reflux. However, prospective studies assessing the role of lifestyle modification in those with suspected or proven reflux-related extraesophageal symptoms are needed. Until then a prudent recommendation is to use head-of-bed elevation only in patients who have concomitant regurgitation or nocturnal heartburn, which might result in silent or overt contact of the larynx or lung to gastroduodenal contents at nights when patients are in the supine position. Avoiding trigger foods may be recommended only if patients report worsening of extraesophageal symptoms after certain food intake. Finally, in patients suspected of refluxrelated laryngeal symptoms, especially in those with concomitant heartburn and regurgitation who may be overweight or obese, implementation of a weight loss program is effective in treating esophageal acid exposure. However, the role of weight loss in improving or alleviating specifically extraesophageal symptoms awaits future evidence.
Medical Therapy
Medical therapy is the mainstay of treating patients with reflux disease. 64, 66 Overall, antacid and alginic acid provide temporary relief and as such are not optimal in treating chronic reflux. The cornerstone of therapy in extraesophageal reflux is the administration of agents that decrease gastric acid secretion, thereby reducing esophageal acid exposure. Histamine receptor antagonists (H2RAs) in standard divided doses achieve healing of esophagitis in about 50% of patients. They are typically most useful for patients with intermittent or mild reflux disease. The role of H2RAs in patients with extraesophageal reflux is less well established in maintaining nocturnal gastric pH >4. Randomized controlled trials using H2RAs (cimetidine or ranitidine), mostly conducted before availability of PPIs, showed conflicting results with respect to the outcome of asthma symptom improvement. [72] [73] [74] [75] [76] Overall, these studies showed some subjective improvement in asthma symptoms and a trend toward improvement in pulmonary function in an adult population with a minimum of 4 weeks of treatment.
However, heterogeneity of the population and small sample sizes are important limitations of these reports.
Acid suppression with PPI therapy is the current standard in treating patients with GERD. Studies have shown that PPIs are superior to H2RAs, sucralfate, or placebo in both healing of esophagitis and relieving of heartburn. 77, 78 However, the effectiveness of PPI therapy in patients with extraesophageal reflux is less robust. In treating patients with asthma, studies have used different endpoints regarding efficacy of acidsuppressive therapy. Some used forced expiratory volume in 1 second, whereas others used patient-reported symptom outcome or change in medication use. Earlier studies were positive regarding the benefit of PPI therapy in asthma control, [79] [80] [81] [82] [83] whereas more recent studies have questioned their impact. 23, 84 A study conducted by the American Lung Association Asthma Clinical Research Center randomized 412 patients with poor asthma control to either esomeprazole, 40 mg twice daily, or placebo. After 24 weeks of follow-up, the study found no benefit to PPI therapy in asthma control. 23 Similarly, a randomized control trial in children with asthma without overt GERD did not show a benefit to lansoprazole in symptom or lung function improvement. 84 However, a clue as to which subgroup of patients with asthma might benefit from acid-suppressive therapy has come from a controlled trial suggesting therapeutic benefit of PPI in the subgroup with both nocturnal respiratory and typical reflux symptoms. 83 This is an important observation that is similarly emphasized in studies of patients with suspected reflux-related laryngitis treated with antireflux surgery outlined below.
PPI treatment is often used in patients suspected of having reflux-related laryngeal symptoms and signs also termed LPR. However, substantive evidence for impact of this approach is sparse and in need of clarity. Openlabeled studies are more enthusiastic about improvement of nonspecific laryngeal signs and symptoms with reported response ranging from 47% to 90%. 85, 86 In 1 randomized trial of rabeprazole, 20mg twice daily, versus placebo in patients with suspected LPR there was a significant improvement in symptom index score in those on PPI therapy compared with placebo but without a difference in laryngeal signs. 87 However, results from the largest study to date in this area were less enthusiastic. This multicenter randomized double-blinded study of 145 patients suspected of LPR did not show a benefit in those treated for 4-months with esomeprazole, 40 mg twice daily, compared with placebo. 21 Three subsequent meta-analyses of controlled studies in LPR have suggested no benefit to PPI therapy overall; however, there was evidence that a subgroup of patients may benefit from such therapy. 9, 88, 89 Similar to patients with asthma and LPR, those with chronic cough are often treated with PPI therapy based on earlier studies suggesting that GERD is the third most common cause of chronic cough. 90, 91 The recommendation of empiric therapy for reflux-related cough is solely based on open-label trials because placebo-controlled studies do not support a benefit to PPI therapy in this group. In 1 open-label study, 79% of patients with chronic cough improved after empiric trial of PPI therapy. 92 However, a meta-analysis of 5 placebo-controlled studies in adults with chronic cough found insufficient evidence in favor of PPI therapy. 22 Most recently 2 additional randomized controlled trials did not find any benefit to PPI therapy compared with placebo in adult subjects with chronic cough. 93, 94 Based on these observations the most recent expert panel guidelines have deemphasized the role of acid-suppressive therapy in those with unexplained chronic cough. 95 Recent data suggest that there may be a benefit to PPI therapy in those with chronic cough and concomitant objective reflux. 96 Thus, emerging data are emphasizing the role of PPI therapy in patients suspected of having extraesophageal reflux who have concomitant typical symptoms, such as heartburn and regurgitation, while questioning the impact of such therapy in those solely with extraesophageal symptoms.
There are limited data regarding the benefit of prokinetic agents in patients with suspected extraesophageal reflux. A small number of randomized trials have shown conflicting results. Uncontrolled retrospective studies published in only abstract form demonstrated some improved symptoms. 97, 98 Four randomized control studies assessed the effect of added itopride, domperidone, or tegaserod to PPI therapy versus PPI therapy alone. [99] [100] [101] [102] Three of the 4 studies suggested reduction in symptoms on a prokinetic plus PPI versus PPI treatment alone but no change in laryngeal findings were noted in most studies. A meta-analysis of the randomized trials using prokinetic therapy in suspected extraesophageal reflux suggested that the current body of evidence is inadequate to make a recommendation for their use based on available data. 103 Baclofen, a g-aminobutyric acid type B receptor agonist, inhibits transient lower esophageal sphincter relaxation and is shown to be effective in reducing reflux events in GERD and healthy control subjects. 104 The role of baclofen in patients suspected of having extraesophageal reflux is uncertain. Two studies explored the use of this agent in patients with chronic cough. 105, 106 In 1 case series of 3 patients with cough treatment, baclofen resulted in improvement or resolution of chronic cough in all 3 patients. 106 In a different study, an 8-week course of baclofen (20 mg, 3 times daily) as an add-on therapy to omeprazole resulted in improvement of cough in 56% of patients who showed reduction in the number of acid reflux episodes. 105 However, there are currently no controlled studies showing benefit of baclofen in extraesophageal reflux.
Alginates decrease GERD by forming a pH-neutral raft near the gastroesophageal junction. In a multicenter randomized controlled study of patients with typical GERD symptoms, it was shown to reduce the severity and frequency of heartburn and frequency of regurgitation in patients with continued symptoms despite once-daily PPI therapy. 107 In an earlier study, this compound was used in patients with LPR who received either placebo or liquid alginate suspension and were assessed for symptom and laryngeal sign changes at 2, 4, and 6 months post-therapy. 108 Patients treated with liquid alginate showed a significant improvement of symptoms at all follow-up time points and significant improvement in laryngeal signs at 6 months. The role of these compounds in asthma has not been assessed.
The emerging common theme for medical therapy in those suspected with extraesophageal reflux is that a short course of PPI therapy (likely twice daily for 1-2 months) is sufficient to address the question of reflux association with extraesophageal symptoms. The likely responders might be those with concomitant typical GERD symptoms or pathophysiologic reflux. There are only limited data on the benefit of twice-daily compared to once-daily PPI therapy in this group. The evidence is weak and based on open-label trials. 85 However, it makes physiologic sense because twice-daily PPI ensures near complete esophageal reflux control in 95%-99% of patients. 109 In those with lack of benefit to twice-daily PPI therapy and without regurgitation to suggest increased nonacid reflux, GERD can be excluded and a search for other etiologies should ensue. Among those whose extraesophageal reflux responds to PPI therapy, tapering of the dose to once daily and subsequently to minimum dose of acid-suppressive therapy necessary is prudent.
Summary. There are low-quality data to suggest that medical therapy is effective for treating extraesophageal symptoms attributed to GERD. However, an empiric course of twice-daily PPI should be considered particularly in patients with more typical symptoms and/or findings of GERD or in those patients who have had a prior thorough evaluation and treatment course for causes other than GERD.
Surgical Therapy
There are currently no randomized trials comparing the efficacy of surgical antireflux therapy with PPI therapy. Only 1 study compared the efficacy of Nissen fundoplication with H2RAs in a group of patients with GERD and asthma showing 75% improvement after 2 years in the surgically treated patients compared with 9% of those on H2RAs. 72 Concern about using antireflux surgery in extraesophageal reflux is a high risk-to-benefit ratio using this treatment option given the lack of robust evidence for its benefit. Most surgical data in chronic cough, [110] [111] [112] LPR, [113] [114] [115] [116] [117] [118] [119] [120] [121] and asthma 39, 72, [122] [123] [124] [125] [126] [127] are uncontrolled, retrospective, and suffer from small sample sizes. Despite enthusiasm from observational and case series reporting improvement of extraesophageal reflux symptoms, most surgeons shy away from offering fundoplication to patients with extraesophageal reflux symptoms without typical heartburn and/or regurgitation. In fact, a recent study assessing the impact of surgical fundoplication in a group of patients with esophageal and extraesophageal syndrome showed that the latter are less likely to have symptom improvement or resolution with surgery and the best predictor of response in both groups is prior symptom response to PPI therapy. 128 Additionally, a concurrent controlled study in patients with laryngeal symptoms refractory to PPI therapy showed no benefit to surgery at 1-year follow-up compared with continued PPI treatment. 129 The results of this study are important in that some have argued that intermittent reflux might be responsible for continued laryngeal symptoms and acidsuppressive therapy alone may fall short recommending surgery as the definitive option. However, in the study by Swoger et al 129 only 10% and 7% of patients in the surgery and continued medical therapy, respectively, improved at 1 year.
Emerging data suggest that a select patient population may benefit from surgery. This includes those with known structural defects, such as hiatal hernia, leading to symptomatic volume-based regurgitation and possibly objectively measured by a combination of pH and impedance monitoring. 130 Thus, based on current evidence we recommend a cautious approach in recommending surgical therapy in extraesophageal reflux. Surgical fundoplication might be beneficial in those with known response of extraesophageal symptoms to PPI therapy who are (1) unwilling to take PPIs chronically, and/or (2) have side effects with PPI therapy, or (3) have continued regurgitation with mechanical defect (hiatal hernia) despite PPI therapy.
Summary. Surgical therapy for extraesophageal symptoms is highly discouraged but may be considered in patients with objective evidence of GERD refractory to medical therapy and lack of response to comprehensive non-GERD therapy.
Conclusions
Emerging new data in diagnostic tests and treatment outcome suggests that reflux could be causal in a subgroup of patients with extraesophageal reflux, although the degree has been overestimated. Furthermore, the cause of extraesophageal symptoms in many patients is often multifactorial rather than from reflux alone. The role of diagnostic testing in this group is to establish presence and degree of reflux and assess the likelihood that it may be linked to patients' symptoms. Figure 1 outlines a recommended algorithm in this group of patients based on current available data. Diagnostic testing is recommended after a course of high-dose empiric acid suppression to after which symptoms remain. Patients with extraesophageal symptoms without concomitant typical reflux symptoms, such as heartburn or regurgitation, are less likely to benefit from aggressive reflux therapies. Escalation of therapy may be justified in those with mechanical barrier issues, such as a large hiatal hernia and proven significant reflux. In those unresponsive to a course of medical therapy that is proven objectively to control reflux, de-escalation of acidsuppression therapy and investigation into other potential causes for patients' continued extraesophageal reflux are recommended. 
